MAb-362 (Massachusetts Biologic Laboratories)

N/A

Report date: 2025/01/26 18:50:43

Base Information

Drug NameMAb-362 (Massachusetts Biologic Laboratories)
Drug Alias NameMAb-362IgACOVID-19 specific IgA monoclonal antibody (Masssachusetts Biologic Laboratories)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAngiotensin-converting enzyme 2 inhibitorsCoronavirus spike glycoprotein inhibitors
TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMassachusetts Biologic Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts Biologic Laboratories
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A